Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Oct 11;14:5789. doi: 10.1038/s41467-023-41328-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2023

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 6 — Newly-onset, untreated patients with MPA (n = 8) and healthy donors (n = 7) were recruited for this study. MPA is characterized by increased proportions of cytotoxic CD8⁺ T cells, KIR⁺ CD8⁺ T cells, activated CD14⁺ monocytes, CD14⁺ monocytes with ISG expression, CD69⁺ naïve B cells, plasmablasts, and plasma cells. MPA was further subclassified into two groups based on the high expression of CD14⁺ monocytes signature genes (MPA-MONO) or high expression of ISGs (MPA-IFN). The percentage of monocytes and serum IFN-α levels were the clinical markers that clearly distinguished MPA-MONO and MPA-IFN groups, respectively. The findings of this study suggest clinical recommendations for estimating prognosis for each patient based on the immunological phenotypes of MPA. MPA microscopic polyangiitis, PBMC peripheral blood mononuclear cells, CITE-seq cellular indexing of transcriptomes and epitopes by sequencing, CyTOF cytometry by time-of-flight, CTL cytotoxic T lymphocytes, KIR killer immunoglobulin-like receptor, ISG interferon signature genes, MAIT mucosal associated invariant T cells, cDC classical dendritic cells, gdT gamma-delta T cells, CBC complete blood count.